Healthcare >> CEO Interviews >> August 6, 2001

Steven Quay – Nastech Pharmaceutical Company Inc (nstk)

DR. STEVEN C. QUAY has been employed by Nastech Pharmaceutical Company Inc. since August 2000 as Chairman of the Board, President and Chief Executive Officer. In 1999, Dr. Quay founded and was Chairman, President and Chief Executive Officer of Atossa, which focused on the development of a proprietary platform of diagnostics and treatments related to breast cancer risk assessment and therapeutics and other healthcare products for women. Nastech acquired Atossa in August 2000. In 1991, Dr. Quay founded Sonus Pharmaceuticals, Inc., a company engaged in the research and development of drug delivery systems and oxygen delivery products based on emulsion and surfactant technology, where he served as Chief Executive Officer, President and a Director until June 1999. In 1984, Dr. Quay founded Salutar, Inc., to develop contrast agents for magnetic resonance imaging. Two pharmaceuticals, OmniScan' and TeslaScan', were invented by Dr. Quay at Salutar and are now FDA- approved for sale in the United States and other countries. Dr. Quay has authored more than 100 papers in diagnostic imaging, oncology and biochemistry and holds 51 US patents. Dr. Quay graduated from the University of Michigan Medical School, where he received an MA and a PhD in Biological Chemistry in 1974 and 1975, respectively, and an MD in 1977. Dr. Quay completed his post-graduate work in the Chemistry Department of Massachusetts Institute of Technology and received his residency training at Massachusetts General Hospital, Harvard Medical School in Boston. From 1980 to 1986, he was a faculty member of Stanford University School of Medicine. Profile
TWST: Let's begin with an update on Nastech Pharmaceutical Company. What

has happened over the past couple of quarters that investors should be

aware of?

Dr. Quay: We've made significant